Suppr超能文献

早期采用多靶点粪便DNA检测进行结直肠癌筛查。

Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.

作者信息

Finney Rutten Lila J, Jacobson Robert M, Wilson Patrick M, Jacobson Debra J, Fan Chun, Kisiel John B, Sweetser Seth, Tulledge-Scheitel Sidna M, St Sauver Jennifer L

机构信息

Population Health Science Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

Population Health Science Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Division of Community Pediatric and Adolescent Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN.

出版信息

Mayo Clin Proc. 2017 May;92(5):726-733. doi: 10.1016/j.mayocp.2017.01.019.

Abstract

OBJECTIVES

To characterize early adoption of a novel multitarget stool DNA (MT-sDNA) screening test for colorectal cancer (CRC) screening and to test the hypothesis that adoption differs by demographic characteristics and prior CRC screening behavior and proceeds predictably over time.

PATIENTS AND METHODS

We used the Rochester Epidemiology Project research infrastructure to assess the use of the MT-sDNA screening test in adults aged 50 to 75 years living in Olmsted County, Minnesota, in 2014 and identified 27,147 individuals eligible or due for screening colonoscopy from November 1, 2014, through November 30, 2015. We used electronic Current Procedure Terminology and Health Care Common Procedure codes to evaluate early adoption of the MT-sDNA screening test in this population and to test whether early adoption varies by age, sex, race, and prior CRC screening behavior.

RESULTS

Overall, 2193 (8.1%) and 974 (3.6%) individuals were screened by colonoscopy and MT-sDNA, respectively. Age, sex, race, and prior CRC screening behavior were significantly and independently associated with MT-sDNA screening use compared with colonoscopy use after adjustment for all other variables (P<.05 for all). The rates of adoption of MT-sDNA screening increased over time and were highest in those aged 50 to 54 years, women, whites, and those who had a history of screening. The use of the MT-sDNA screening test varied predictably by insurance coverage. The rates of colonoscopy decreased over time, whereas overall CRC screening rates remained steady.

CONCLUSION

The results of the present study are generally consistent with predictions derived from prior research and the diffusion of innovation framework, pointing to increasing use of the new screening test over time and early adoption by younger patients, women, whites, and those with prior CRC screening.

摘要

目的

描述一种用于结直肠癌(CRC)筛查的新型多靶点粪便DNA(MT-sDNA)筛查试验的早期采用情况,并检验以下假设:采用情况因人口统计学特征和既往CRC筛查行为而异,且随时间推移具有可预测性。

患者与方法

我们利用罗切斯特流行病学项目的研究基础设施,评估了2014年居住在明尼苏达州奥尔姆斯特德县的50至75岁成年人中MT-sDNA筛查试验的使用情况,并确定了2014年11月1日至2015年11月30日期间符合条件或应接受结肠镜筛查的27147名个体。我们使用电子当前操作术语和医疗保健通用程序编码来评估该人群中MT-sDNA筛查试验的早期采用情况,并检验早期采用是否因年龄、性别、种族和既往CRC筛查行为而有所不同。

结果

总体而言,分别有2193名(8.1%)和974名(3.6%)个体接受了结肠镜检查和MT-sDNA筛查。在对所有其他变量进行调整后,与结肠镜检查相比,年龄、性别、种族和既往CRC筛查行为与MT-sDNA筛查的使用显著且独立相关(所有P<0.05)。MT-sDNA筛查的采用率随时间增加,在50至54岁的人群、女性、白人以及有筛查史的人群中最高。MT-sDNA筛查试验的使用因保险覆盖情况而异,具有可预测性。结肠镜检查的比率随时间下降,而总体CRC筛查率保持稳定。

结论

本研究结果总体上与先前研究和创新扩散框架得出的预测一致,表明随着时间推移,新筛查试验的使用增加,年轻患者、女性、白人以及有既往CRC筛查史的患者早期采用该试验。

相似文献

1
Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
Mayo Clin Proc. 2017 May;92(5):726-733. doi: 10.1016/j.mayocp.2017.01.019.
2
Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
World J Gastroenterol. 2017 Jan 21;23(3):464-471. doi: 10.3748/wjg.v23.i3.464.
3
Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Gastroenterology. 2016 Sep;151(3):427-439.e6. doi: 10.1053/j.gastro.2016.06.003. Epub 2016 Jun 14.
4
Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Public Health. 2020 May;182:70-76. doi: 10.1016/j.puhe.2020.01.021. Epub 2020 Mar 13.
5
Performance of multitarget stool DNA testing in African American patients.
Cancer. 2018 Oct 1;124(19):3876-3880. doi: 10.1002/cncr.31660. Epub 2018 Sep 7.
7
Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
J Prim Care Community Health. 2019 Jan-Dec;10:2150132719884295. doi: 10.1177/2150132719884295.
8
Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Cancer Prev Res (Phila). 2021 Sep;14(9):845-850. doi: 10.1158/1940-6207.CAPR-21-0075. Epub 2021 May 21.
10
Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
Clin Colorectal Cancer. 2016 Sep;15(3):e65-74. doi: 10.1016/j.clcc.2015.12.003. Epub 2015 Dec 18.

引用本文的文献

1
Diagnostic accuracy of the multi-target stool DNA test in detecting colorectal cancer: A hospital-based study.
World J Gastrointest Oncol. 2023 Jan 15;15(1):102-111. doi: 10.4251/wjgo.v15.i1.102.
2
Colorectal Cancer Screening With the Multitarget Stool DNA Test.
Am J Gastroenterol. 2020 Nov;115(11):1737-1740. doi: 10.14309/ajg.0000000000000968.
3
Colorectal cancer screening completion: An examination of differences by screening modality.
Prev Med Rep. 2020 Sep 11;20:101202. doi: 10.1016/j.pmedr.2020.101202. eCollection 2020 Dec.
4
Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions.
Gastrointest Endosc Clin N Am. 2020 Jul;30(3):553-568. doi: 10.1016/j.giec.2020.02.008. Epub 2020 Apr 16.
6
DNA methylation detection methods used in colorectal cancer.
World J Clin Cases. 2019 Oct 6;7(19):2916-2929. doi: 10.12998/wjcc.v7.i19.2916.
7
Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.
PLoS One. 2019 Sep 4;14(9):e0220234. doi: 10.1371/journal.pone.0220234. eCollection 2019.
8
Performance of multitarget stool DNA testing in African American patients.
Cancer. 2018 Oct 1;124(19):3876-3880. doi: 10.1002/cncr.31660. Epub 2018 Sep 7.

本文引用的文献

2
Multitarget stool DNA testing for colorectal-cancer screening.
N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.
3
Vital signs: colorectal cancer screening test use--United States, 2012.
MMWR Morb Mortal Wkly Rep. 2013 Nov 8;62(44):881-8.
4
Commentary: Representativeness is usually not necessary and often should be avoided.
Int J Epidemiol. 2013 Aug;42(4):1018-22. doi: 10.1093/ije/dyt103.
5
Why representativeness should be avoided.
Int J Epidemiol. 2013 Aug;42(4):1012-4. doi: 10.1093/ije/dys223.
8
History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.
Mayo Clin Proc. 2012 Dec;87(12):1202-13. doi: 10.1016/j.mayocp.2012.08.012. Epub 2012 Nov 28.
10
Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study.
Mayo Clin Proc. 2012 Jan;87(1):34-40. doi: 10.1016/j.mayocp.2011.09.002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验